Riding the pepTIDE — The Daily Wire on Therapeutic Peptides

An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.

Topic Sections

  • Top Shots — The most significant peptide and longevity stories ranked by overall editorial score
  • Research Signals — High-credibility scientific findings from journals, preprints, and clinical sources
  • Healing & Recovery — Tissue repair, injury recovery, and gut healing peptides including BPC-157 and TB-500
  • Growth Hormone Wire — Growth hormone secretagogues, peptide stacks, and GH axis research including Ipamorelin, CJC-1295, and MK-677
  • Metabolic & GLP-1 — Metabolic health, insulin sensitivity, and GLP-1 receptor agonist research including semaglutide and tirzepatide
  • Cognitive / Nootropic — Peptides targeting brain function, memory, neuroprotection, and cognitive enhancement
  • Skin & Cosmetic — Skin repair, anti-aging, collagen synthesis, and cosmetic peptide research including GHK-Cu and matrixyl
  • Reddit Finds — Community-sourced discussions, self-experimentation reports, and protocol threads from peptide communities
  • Contrarian Takes — Alternative viewpoints, dissenting research, and perspectives that challenge mainstream peptide narratives
  • Skeptic's Corner — Hype debunking, low-evidence alerts, and critical analysis of overstated peptide claims

Browse by Filter

  • Newest — Latest peptide and longevity stories
  • Most Credible — Highest credibility-scored stories
  • Most Edgy — High-novelty, unconventional findings
  • Most Discussed — Trending community discussions
  • Most Actionable — Direct applicability to daily health protocols
  • Lowest Risk — Stories with strong evidence, low hype
  • Research Only — Peer-reviewed and preprint studies
  • Reddit Only — Community discussion and anecdote
  • GLP-1 / Metabolic — Semaglutide, tirzepatide, and metabolic peptides
  • Healing / Recovery — BPC-157, TB-500, and repair protocols

More

  • About Riding the pepTIDE
  • Health Disclaimer
  • Submit a Source
  • Contact

Four Years on Mounjaro: Type 2 Weight Drops From 170 to 108

Someone posted a four-year update about using Mounjaro for type 2 diabetes and weight loss. In 2022 they started at 170 (pounds, presumably) and by 2026 they report 108. The note is an anniversary-style progress report, not a formal study. Mounjaro is the brand name for tirzepatide. It’s a prescription injectable medicine originally approved to treat type 2 diabetes. In plain terms, tirzepatide acts like two natural gut hormones that help control blood sugar and appetite. One hormone helps the body respond to insulin and lowers blood sugar; the other helps you feel full and slows how fast food leaves your stomach. That combination tends to reduce hunger and can lead to weight loss as a side effect or additional benefit. That post is an individual’s experience, not a clinical trial result. It suggests a large weight drop over four years — from about 170 to 108 pounds — but it doesn’t provide details like other medications, diet, exercise, starting height, or whether they had medical supervision. Anecdotes like this are useful to show what’s possible, but they don’t tell us how typical the outcome is. Clinical studies of tirzepatide have shown significant average weight loss compared with placebo and some other diabetes drugs, but individual results vary widely. Why this matters: for people with type 2 diabetes or those struggling with obesity under medical care, tirzepatide/Mounjaro has been a game changer for many. It can improve blood sugar control and often causes marked weight loss, which together lower risks for heart disease and other complications. Reading real-life success stories can be encouraging and prompt conversations with a doctor about treatment options. Caveats and risks: this is a single-person report, so you can’t assume everyone will lose the same amount of weight. Tirzepatide can cause side effects like nausea, diarrhea, and stomach pain, especially when doses are increased. There are also longer-term unknowns for people using it primarily for weight loss rather than diabetes. It’s a prescription drug — you should only use it under medical supervision. People with certain conditions (for example, a history of pancreatitis or some thyroid cancers) might be advised against it. Insurance coverage and cost can also be major barriers. Bottom line: an impressive personal success story for Mounjaro/tirzepatide, but it’s an anecdote; talk to a clinician to understand if the drug is appropriate and what results you might realistically expect.

Source: r/Mounjaro

Read full story

Back to Riding the pepTIDE